A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors.

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Opens in a new tab or window SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists were more cardioprotective in younger people ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 ... DPP4 inhibitors, and SGLT2 inhibitors (536,068 people), as well as a control group that ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists ... SGLT2 inhibitors (536,068 people), as well as a control group that continued use of non-GLP ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA ... and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated ...